Aicdatm1(cre)Mnz/Aicda+
Ightm3Mnz/Igh+
Myctm39Mnz/Myc+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:145691
|
|
spontaneous chromosome breakage |
J:145691
|
Aicdatm1(cre)Mnz/Aicda+
Ightm3Mnz/Igh+
Myctm37Mnz/Myc+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:145691
|
|
spontaneous chromosome breakage |
J:145691
|
Aicdatm1Hon/Aicdatm1Hon
Ightm3Mnz/Igh+
Myctm37Mnz/Myc+
involves: C57BL/6 * CBA
|
induced chromosome breakage |
J:145691
|
ApcMin/Apc+
Myctm1Jlc/Myc+
involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J
|
abnormal digestive system physiology |
J:134087
|
|
abnormal hematopoietic system morphology/development |
J:134087
|
|
normal
hematopoietic system phenotype |
J:134087
|
|
intestine polyps |
J:134087
|
|
normal
mortality/aging |
J:134087
|
Atg5tm1.1Myok/Atg5tm1.1Myok
Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/Col1a1+
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N
|
abnormal cell physiology |
J:205532
|
Atmtm1Awb/Atmtm1Awb
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
involves: 129 * C57BL * FVB/N * SJL
|
increased tumor incidence |
J:120284
|
|
premature death |
J:120284
|
Atmintm1.1Jhh/Atmintm1.1Jhh
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast
Cd79atm1(cre)Reth/Cd79a+
Tg(IghMyc)22Bri/0
B6.Cg-Bcl2l11tm1.1Ast Cd79atm1(Cre)Reth Atmintm1.1Jhh Tg(IghMyc)22Bri
|
increased lymphoma incidence |
J:230105
|
Atmintm1.1Jhh/Atmintm1.1Jhh
Cd79atm1(cre)Reth/Cd79a+
Tg(IghMyc)22Bri/0
B6.Cg-Cd79atm1(Cre)Reth Atmintm1.1Jhh Tg(IghMyc)22Bri
|
decreased B cell number |
J:230105
|
|
decreased immature B cell number |
J:230105
|
|
decreased lymphoma incidence |
J:230105
|
|
increased B cell apoptosis |
J:230105
|
|
increased tumor latency |
J:230105
|
Bcl2l11tm1.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0
involves: C57BL/6 * SJL
|
increased B cell derived lymphoma incidence |
J:186117
|
|
increased leukocyte cell number |
J:186117
|
|
increased T cell derived lymphoma incidence |
J:186117
|
|
premature death |
J:186117
|
Bcl2l11tm1.1Boui/Bcl2l11tm1.1Boui
Tg(IghMyc)22Bri/0
involves: C57BL/6 * SJL
|
increased B cell derived lymphoma incidence |
J:186117
|
|
increased leukocyte cell number |
J:186117
|
|
premature death |
J:186117
|
Bcl2l11tm2.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0
involves: C57BL/6 * SJL
|
increased B cell derived lymphoma incidence |
J:186117
|
|
increased leukocyte cell number |
J:186117
|
|
premature death |
J:186117
|
Bcl2l11tm2.1Boui/Bcl2l11tm2.1Boui
Tg(IghMyc)22Bri/0
involves: C57BL/6 * SJL
|
increased B cell derived lymphoma incidence |
J:186117
|
|
increased leukocyte cell number |
J:186117
|
|
premature death |
J:186117
|
Bcl2l11tm3.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0
involves: C57BL/6 * SJL
|
increased B cell derived lymphoma incidence |
J:186117
|
|
premature death |
J:186117
|
Bcl2l11tm3.1Boui/Bcl2l11tm3.1Boui
Tg(IghMyc)22Bri/0
involves: C57BL/6 * SJL
|
increased B cell derived lymphoma incidence |
J:186117
|
|
premature death |
J:186117
|
Bin1tm1Gcp/Bin1tm2Gcp
Tg(MMTV-Myc)141-3Led/0
Tg(Wap-cre)11738Mam/0
involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL
|
abnormal cell physiology |
J:117330
|
|
abnormal enzyme/coenzyme activity |
J:117330
|
|
decreased apoptosis |
J:117330
|
|
increased cell proliferation |
J:117330
|
|
increased lymphoma incidence |
J:117330
|
|
increased mammary adenocarcinoma incidence |
J:117330
|
Boktm1.1Ast/Boktm1.1Ast
Tg(IghMyc)22Bri/0
involves: BALB/cJ * C57BL * C57BL/6 * SJL
|
increased lymphoma incidence |
J:203179
|
Cd79atm1(cre)Reth/Cd79a+
Dynll1tm1.1Jhh/Dynll1tm1.1Jhh
Tg(IghMyc)22Bri/0
B6.Cg-Dynll1tm1.1Jhh Cd79atm1(Cre)Reth Tg(IghMyc)22Bri
|
decreased immature B cell number |
J:230105
|
|
decreased lymphoma incidence |
J:230105
|
Cdc25atm1Kiyo/Cdc25a+
Tg(MMTV-Myc)141-3Led/?
involves: 129/Sv * C57BL/6 * C57BL/6J * CD-1
|
normal
neoplasm |
J:123144
|
Cdkn1btm1Mlf/Cdkn1b+
Myctm1Atp/Myc+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N
|
decreased body size |
J:73369
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Myctm1Atp/Myc+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N
|
decreased body size |
J:73369
|
|
decreased T cell proliferation |
J:73369
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Myctm1Atp/Myctm1Atp
involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N
|
prenatal lethality, complete penetrance |
J:73369
|
Cdkn2atm1Cjs/Cdkn2a+
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
involves: 129 * C57BL * FVB/N * SJL
|
decreased tumor incidence |
J:120284
|
|
premature death |
J:120284
|
Cks1btm1Sir/Cks1b+
Tg(IghMyc)22Bri/?
involves: C57BL * C57BL/6 * SJL
|
increased lymphoma incidence |
J:121564
|
|
premature death |
J:121564
|
Cks1btm1Sir/Cks1btm1Sir
Tg(IghMyc)22Bri/?
involves: C57BL * C57BL/6 * SJL
|
decreased B cell proliferation |
J:121564
|
|
decreased leukocyte cell number |
J:121564
|
|
decreased lymphocyte cell number |
J:121564
|
|
decreased metastatic potential |
J:121564
|
|
decreased spleen weight |
J:121564
|
|
increased lymphoma incidence |
J:121564
|
|
premature death |
J:121564
|
Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
no abnormal phenotype detected |
J:157298
|
Crebbptm2Pkb/Crebbp+
Tg(IghMyc)22Bri/0
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
abnormal tumor incidence |
J:103607
|
Cul9tm1.2Yxi/Cul9+
Tg(IghMyc)22Bri/0
involves: 129P2/OlaHsd * C57BL * C57BL/6 * FVB/N * SJL
|
abnormal tumor pathology |
J:170976
|
|
increased B cell derived lymphoma incidence |
J:170976
|
|
increased lymphoma incidence |
J:170976
|
|
premature death |
J:170976
|
Cul9tm1.2Yxi/Cul9tm1.2Yxi
Tg(IghMyc)22Bri/0
involves: 129P2/OlaHsd * C57BL * C57BL/6 * FVB/N * SJL
|
abnormal tumor pathology |
J:170976
|
|
increased B cell derived lymphoma incidence |
J:170976
|
|
increased lymphoma incidence |
J:170976
|
|
premature death |
J:170976
|
Del(15Rr316124-Rr313939)2Fsp/+
Myctm1Atp/Myc+
involves: 129P2/OlaHsd * C57BL/6
|
decreased B cell number |
J:257739
|
|
decreased bone marrow cell number |
J:257739
|
|
decreased granulocyte number |
J:257739
|
|
normal
hematopoietic system phenotype |
J:257739
|
|
increased megakaryocyte cell number |
J:257739
|
|
increased myeloid cell number in bone marrow |
J:257739
|
Dmtf1tm1Cjs/Dmtf1+
Tg(IghMyc)22Bri/0
involves: 129/Sv * C57BL * C57BL/6 * SJL
|
decreased tumor latency |
J:72617
|
Dnmt1tm1(tetO-BCL2)Sjk/Dnmt1+
Tg(IghMyc)22Bri/0
Tg(MMTVtTA)1Mam/0
involves: 129S4/SvJae * C57BL/6
|
enlarged spleen |
J:93549
|
|
increased B cell derived lymphoma incidence |
J:93549
|
|
increased leukemia incidence |
J:93549
|
|
lethargy |
J:93549
|
|
premature death |
J:93549
|
Ep300tm3Pkb/Ep300+
Tg(IghMyc)22Bri/0
involves: 129S6/SvEvTac * C57BL * SJL
|
abnormal tumor susceptibility |
J:103607
|
Ep300tm3Pkb/Ep300+
Tg(IghMyc)22Bri/0
involves: 129S6/SvEvTac * C57BL/6
|
abnormal tumor incidence |
J:103607
|
Fbxw7tm1Kei/Fbxw7tm1Kei
Myctm2Fwa/Myctm2Fwa
Tg(Cd4-cre)1Cwi/?
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2
|
normal
immune system phenotype |
J:128523
|
Fnip1LPAB.1/Fnip1LPAB.1
Tg(IghMyc)22Bri/0
involves: C57BL * C57BL/6J * SJL
|
increased B cell apoptosis |
J:187318
|
|
normal
neoplasm |
J:187318
|
Gt(ROSA)26Sortm12(CD2*)Rsky/Gt(ROSA)26Sor+
Myctm2Fwa/Myctm2Fwa
Ighg1tm1(cre)Cgn/Ighg1+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6
|
decreased spleen germinal center size |
J:188564
|
Gt(ROSA)26Sortm13(CAG-MYC,-CD2*)Rsky/Gt(ROSA)26Sor+
Myctm2Fwa/Myctm2Fwa
Ighg1tm1(cre)Cgn/Ighg1+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6
|
normal
immune system phenotype |
J:188564
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
involves: C57BL/6 * CBA
|
abnormal hepatocyte morphology |
J:34434
|
|
increased hepatocellular carcinoma incidence |
J:34434,
J:101128
|
|
increased liver adenoma incidence |
J:34434
|
|
increased liver tumor incidence |
J:101128
|
|
increased liver weight |
J:34434
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
involves: C57BL/6J * CBA/J
|
abnormal circadian behavior |
J:190478
|
|
abnormal eating behavior |
J:190478
|
|
decreased body weight |
J:190478
|
|
impaired coordination |
J:190478
|
|
postnatal growth retardation |
J:190478
|
|
slow postnatal weight gain |
J:190478
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
Tg(MtTGFA)42Lmb/0
involves: C57BL/6 * CBA * CD-1
|
abnormal hepatocyte morphology |
J:34434
|
|
increased hepatocellular carcinoma incidence |
J:34434
|
|
increased hepatocyte apoptosis |
J:34434
|
|
increased hepatocyte karyomegaly |
J:34434
|
|
increased liver adenoma incidence |
J:34434
|
|
increased liver weight |
J:34434
|
|
multifocal hepatic necrosis |
J:34434
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
Tg(Alb-E2F1)8Sst/0
involves: C57BL/6 * CBA
|
increased hepatocellular carcinoma incidence |
J:101128
|
|
increased liver tumor incidence |
J:101128
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1Tg(Alb1-Myc)166.8Sst
involves: C57BL/6 * CBA
|
abnormal mastication |
J:102709
|
|
asymmetric snout |
J:102709
|
|
decreased body weight |
J:102709
|
|
limb grasping |
J:102709
|
|
malocclusion |
J:102709
|
|
periorbital fullness |
J:102709
|
|
short snout |
J:102709
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1Tg(Alb1-Myc)166.8Sst
involves: C57BL/6J * CBA/J
|
abnormal circadian behavior |
J:190478
|
|
abnormal eating behavior |
J:190478
|
|
abnormal fear/anxiety-related behavior |
J:190478
|
|
abnormal gait |
J:190478
|
|
abnormal jaw morphology |
J:190478
|
|
abnormal nest building behavior |
J:190478
|
|
abnormal response to new environment |
J:190478
|
|
decreased body weight |
J:190478
|
|
decreased grip strength |
J:190478
|
|
decreased vertical activity |
J:190478
|
|
impaired coordination |
J:190478
|
|
increased anxiety-related response |
J:190478
|
|
increased circulating corticosterone level |
J:190478
|
|
increased grooming behavior |
J:190478
|
|
increased response to stress-induced hyperthermia |
J:190478
|
|
limb grasping |
J:190478
|
|
periorbital fullness |
J:190478
|
|
postnatal growth retardation |
J:190478
|
|
short snout |
J:190478
|
|
slow postnatal weight gain |
J:190478
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/0
Tg(MtTGFA)42Lmb/0
involves: C57BL/6 * CBA * CD-1
|
increased hepatocellular carcinoma incidence |
J:4527
|
Hunktm1Lach/Hunk+
Tg(MMTV-Myc)#Led/0
involves: 129P2/OlaHsd * C57BL/6J * CD-1
|
decreased metastatic potential |
J:153075
|
Hunktm1Lach/Hunktm1Lach
Tg(MMTV-Myc)#Led/0
involves: 129P2/OlaHsd * C57BL/6J * CD-1
|
decreased metastatic potential |
J:153075
|
Ightm1(Myc)Janz/Igh+
involves: 129X1/SvJ * C57BL/6
|
abnormal tumor morphology |
J:160845
|
|
enlarged lymph nodes |
J:96785
|
|
enlarged spleen |
J:96785
|
|
increased B cell apoptosis |
J:96785
|
|
increased B cell derived lymphoma incidence |
J:96785,
J:160845
|
|
increased B cell proliferation |
J:96785
|
|
increased plasmacytoma incidence |
J:96785,
J:160845
|
|
increased tumor incidence |
J:96785,
J:160845
|
|
lymphoid hyperplasia |
J:96785
|
Ightm1(Myc)Janz/Igh+
Mdm4tm1.1Wahl/Mdm4tm1.1Wahl
involves: 129S/Sv * C57BL/6
|
enlarged liver |
J:150341
|
|
enlarged lymph nodes |
J:150341
|
|
enlarged spleen |
J:150341
|
|
increased B cell derived lymphoma incidence |
J:150341
|
|
increased lymphoma incidence |
J:150341
|
|
increased splenocyte proliferation |
J:150341
|
|
premature death |
J:150341
|
Ightm1(Myc)Janz/Igh+
Tg(Emu-FGFR3)A5Wmk/0
involves: 129X1/SvJ * C57BL/6 * FVB/N
|
abnormal tumor morphology |
J:160845
|
|
increased B cell derived lymphoma incidence |
J:160845
|
|
increased plasmacytoma incidence |
J:160845
|
|
increased tumor incidence |
J:160845
|
Ightm1(Myc)Janz/Igh+
Tg(Emu-FGFR3)D3Wmk/0
involves: 129X1/SvJ * C57BL/6 * FVB/N
|
abnormal tumor morphology |
J:160845
|
|
increased B cell derived lymphoma incidence |
J:160845
|
|
increased plasmacytoma incidence |
J:160845
|
|
increased tumor incidence |
J:160845
|
Ighatm1(Myc)Janz/Igha+
involves: 129S1/Sv * C57BL/6
|
increased B cell apoptosis |
J:90901
|
|
increased B cell derived lymphoma incidence |
J:90901
|
|
increased B cell proliferation |
J:90901
|
|
increased plasma cell number |
J:90901
|
Ighatm1(Myc)Janz/Igha+
Tg(Tnfsf13b)1Fma/0
involves: 129S1/Sv * C57BL/6 * DBA/2J
|
enlarged spleen |
J:166158
|
|
increased B cell number |
J:166158
|
|
increased chronic lymphocytic leukemia incidence |
J:166158
|
|
increased lymphocyte cell number |
J:166158
|
|
increased mature B cell number |
J:166158
|
|
increased spleen white pulp amount |
J:166158
|
|
premature death |
J:166158
|
Ighatm1(Myc)Janz/Igha+
Tg(Igk-V21-Bax)1967Bvn/0
involves: 129S1/Sv * C57BL/6 * FVB/N
|
abnormal B cell apoptosis |
J:90901
|
|
abnormal plasma cell morphology |
J:90901
|
|
decreased tumor-free survival time |
J:90901
|
|
enlarged spleen |
J:90901
|
|
increased IgG level |
J:90901
|
|
increased IgM level |
J:90901
|
|
increased leukemia incidence |
J:90901
|
|
increased plasma cell number |
J:90901
|
|
increased plasmacytoma incidence |
J:90901
|
Ighmtm1Cgn/Ighmtm1Cgn
Tg(IghMyc)22Bri/0
involves: 129S2/SvPas * C57BL * SJL
|
increased lymphoma incidence |
J:187318
|
Il15tm1Imx/Il15+
Myctm1Atp/Myc+
involves: 129P2/OlaHsd * C57BL/6
|
decreased memory T cell number |
J:132730
|
Il15tm1Imx/Il15tm1Imx
Myctm1Atp/Myc+
involves: 129P2/OlaHsd * C57BL/6
|
decreased memory T cell number |
J:132730
|
|
decreased NK cell number |
J:132730
|
Kat5tm1Jwl/Kat5+
Tg(IghMyc)22Bri/0
involves: 129S1/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL
|
abnormal B cell physiology |
J:125164
|
|
abnormal DNA repair |
J:125164
|
|
increased B cell derived lymphoma incidence |
J:125164
|
|
premature death |
J:125164
|
Kat5tm1Jwl/Kat5+
Tg(IghMyc)22Bri/0
Trp53tm1Tyj/Trp53+
involves: 129 * C57BL * C57BL/6 * SJL
|
increased B cell derived lymphoma incidence |
J:125164
|
|
premature death |
J:125164
|
Klrb1btm1.1Apma/Klrb1btm1.1Apma
Tg(IghMyc)22Bri/0
involves: BALB/c * C57BL * C57BL/6 * SJL
|
decreased tumor latency |
J:222057
|
Klrk1tm1Dhr/Klrk1tm1Dhr
Tg(IghMyc)22Bri/?
involves: C57BL/6 * CD-1
|
increased B cell derived lymphoma incidence |
J:134509
|
Lect2tm1Ymg/Lect2tm1Ymg
Tg(Pklr-Myc)73Ak/0
B6.Cg-Lect2tm1Ymg Tg(Pklr-Myc)73Ak
|
increased hepatocellular carcinoma incidence |
J:184496
|
|
increased malignant tumor incidence |
J:184496
|
Lrfn2Tg(CD2-Myb/en)5Kmw/Lrfn2+
Tg(H2-K-Myc)1Brn/?
involves: C57BL/10 * CBA * FVB/N
|
abnormal bone marrow cell morphology/development |
J:125805
|
|
abnormal common myeloid progenitor cell morphology |
J:125805
|
|
abnormal erythropoiesis |
J:125805
|
|
abnormal lymph node morphology |
J:125805
|
|
enlarged lymph nodes |
J:125805
|
|
enlarged spleen |
J:125805
|
|
extramedullary hematopoiesis |
J:125805
|
|
lymph node hemorrhage |
J:125805
|
|
lymph node necrosis |
J:125805
|
|
premature death |
J:125805
|
|
spleen hyperplasia |
J:125805
|
Mapk14tm1.1Dvb/Mapk14+
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
involves: 129S7/SvEvBrd * C57BL * FVB/N * SJL
|
decreased tumor incidence |
J:120284
|
|
premature death |
J:120284
|
Mdm2tm1.1Ypz/Mdm2+
Tg(IghMyc)22Bri/0
B6.Cg-Mdm2tm1.1Ypz Tg(IghMyc)22Bri
|
premature death |
J:164200
|
Mdm2tm1.1Ypz/Mdm2tm1.1Ypz
Tg(IghMyc)22Bri/0
B6.Cg-Mdm2tm1.1Ypz Tg(IghMyc)22Bri
|
enlarged liver |
J:164200
|
|
enlarged lymph nodes |
J:164200
|
|
enlarged Peyer's patches |
J:164200
|
|
enlarged thymus |
J:164200
|
|
increased lymphoma incidence |
J:164200
|
|
premature death |
J:164200
|
|
spleen hyperplasia |
J:164200
|
Mdm4tm1Glo/Mdm4+
Tg(IghMyc)22Bri/0
involves: 129S6/SvEvTac * C57BL * C57BL/6 * SJL
|
increased B cell derived lymphoma incidence |
J:123661
|
Mirc1tm2.1Aven/Mirc1+
Tg(IghMyc)22Bri/?
involves: 129S4/SvJae * C57BL/6 * SJL/J
|
abnormal survival |
J:223213
|
Mirc1tm2.1Aven/Mirc1tm2.1Aven
Tg(IghMyc)22Bri/?
involves: 129S4/SvJae * C57BL/6 * SJL/J
|
abnormal pre-B cell morphology |
J:223213
|
|
abnormal survival |
J:223213
|
|
increased B cell apoptosis |
J:223213
|
|
increased B cell derived lymphoma incidence |
J:223213
|
|
increased tumor latency |
J:223213
|
Myctm2Fwa/Myc+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * CD-1
|
decreased osteosarcoma incidence |
J:319454
|
|
increased tumor-free survival time |
J:319454
|
Myctm2Fwa/Myctm2Fwa
Gt(ROSA)26Sortm1Sor/?
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * CBA
|
abnormal coronal suture morphology |
J:121871
|
|
abnormal frontal bone morphology |
J:121871
|
|
abnormal malleus morphology |
J:121871
|
|
short nasal bone |
J:121871
|
|
small malleus |
J:121871
|
|
small malleus manubrium |
J:121871
|
Myctm2Fwa/Myctm2Fwa
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * CD-1
|
premature death |
J:319454
|
Npm1tm1Ppp/Npm1+
Tg(IghMyc)22Bri/0
involves: 129S1/Sv * C57BL/6 * SJL
|
abnormal tumor morphology |
J:101494
|
|
increased B cell derived lymphoma incidence |
J:101494
|
Pknox1tm1Ngc/Pknox1+
Tg(IghMyc)22Bri/0
involves: C57BL * SJL
|
decreased B cell apoptosis |
J:192251
|
|
increased B cell derived lymphoma incidence |
J:192251
|
|
increased B cell proliferation |
J:192251
|
|
premature death |
J:192251
|
Plcg2tm1Jni/Plcg2tm1Jni
Tg(IghMyc)22Bri/0
involves: 129P2/OlaHsd * C57BL * C57BL/6 * SJL
|
enlarged lymph nodes |
J:117023
|
|
increased B cell derived lymphoma incidence |
J:117023
|
|
increased lymphoma incidence |
J:117023
|
|
premature death |
J:117023
|
Ppm1dtm1Lad/Ppm1d+
Tg(IghMyc)22Bri/0
involves: 129S7/SvEvBrd * C57BL * FVB/N * SJL
|
decreased tumor incidence |
J:120284
|
|
premature death |
J:120284
|
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
involves: 129S7/SvEvBrd * C57BL * FVB/N * SJL
|
decreased tumor incidence |
J:120284
|
|
premature death |
J:120284
|
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
Trp53tm1Brd/Trp53+
involves: 129 * C57BL * FVB/N * SJL
|
increased tumor incidence |
J:120284
|
|
premature death |
J:120284
|
Prdm11tm1.1Ahl/Prdm11tm1.1Ahl
Tg(IghMyc)22Bri/0
B6.Cg-Prdm11tm1.1Ahl Tg(IghMyc)22Bri
|
increased B cell derived lymphoma incidence |
J:221379
|
Prps2tm1a(KOMP)Wtsi/Y
Tg(IghMyc)22Bri/0
involves: C57BL/6N * SJL
|
abnormal B cell physiology |
J:214383
|
|
abnormal survival |
J:214383
|
|
normal
hematopoietic system phenotype |
J:214383
|
|
increased B cell apoptosis |
J:214383
|
|
increased tumor latency |
J:214383
|
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
Tg(Pklr-Myc)73Ak/0
B6.Cg-Tcra-Jtm1Tgi Tg(Pklr-Myc)73Ak
|
increased hepatocellular carcinoma incidence |
J:184496
|
|
increased malignant tumor incidence |
J:184496
|
|
increased metastatic potential |
J:184496
|
Tg(ACTB-Eif4e)#Ppp/0
Tg(IghMyc)22Bri/0
involves: C57BL * SJL
|
decreased B cell apoptosis |
J:89878
|
|
increased lymphoma incidence |
J:89878
|
Tg(Alb1-Myc)#Sst/0
Tg(MtTGFA)42Lmb/0
involves: C57BL/6 * CBA * CD-1
|
abnormal hepatocyte morphology |
J:34434
|
|
increased hepatocellular carcinoma incidence |
J:34434
|
|
increased hepatocyte apoptosis |
J:34434
|
|
increased hepatocyte karyomegaly |
J:34434
|
|
increased liver adenoma incidence |
J:34434
|
|
increased liver weight |
J:34434
|
|
multifocal hepatic necrosis |
J:34434
|
Tg(Alb1-Myc)#Sst/0
Tg(MtTGFA)Lmb/0
involves: C57BL/6 * CBA * CD-1
|
decreased NK cell number |
J:176432
|
|
increased hepatocellular carcinoma incidence |
J:176432
|
|
increased NK T cell number |
J:176432
|
Tg(BCL2)22Wehi/0
Tg(IghMyc)22Bri/0
involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi
|
abnormal B cell morphology |
J:69571
|
|
abnormal pre-B cell morphology |
J:69571
|
|
enlarged lymph nodes |
J:69571
|
|
enlarged spleen |
J:69571
|
|
enlarged thymus |
J:69571
|
|
increased B cell number |
J:69571
|
|
increased leukocyte cell number |
J:69571
|
|
increased lymphoma incidence |
J:69571
|
|
increased pre-B cell number |
J:69571
|
|
premature death |
J:69571
|
Tg(EmuSR-tTa)83Bop/0
Tg(IghMyc)22Bri/0
Tg(tetO-RNAi:Trp53)ASlowe/0
involves: C57BL * C57BL/6 * FVB/N * SJL
|
decreased tumor-free survival time |
J:123006
|
|
enlarged spleen |
J:123006
|
|
hindlimb paralysis |
J:123006
|
|
increased lymphoma incidence |
J:123006
|
Tg(Igh-Abl1)40Sco/0
Tg(IghMyc)22Bri/0
involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi
|
enlarged mesenteric lymph nodes |
J:78204
|
|
increased plasmacytoma incidence |
J:78204
|
Tg(IghMyc)22Bri/0
Tg(Igk-V21-Bax)1967Bvn/0
involves: C57BL/6 * FVB/N
|
abnormal liver morphology |
J:89049
|
|
enlarged spleen |
J:89049
|
|
increased B cell derived lymphoma incidence |
J:89049
|
|
increased plasmacytoma incidence |
J:89049
|
|
increased transitional stage B cell number |
J:89049
|
|
premature death |
J:89049
|
Tg(IghMyc)22Bri/0
Tg(Lck/Emu-Eif4e)#Ppp/0
involves: C57BL * SJL
|
increased lymphoma incidence |
J:89878
|
Tg(IghMyc)22Bri/0
Trp53tm1Tyj/Trp53+
involves: 129/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL
|
increased B cell derived lymphoma incidence |
J:125164
|
|
premature death |
J:125164
|
Tg(IghMyc)22Bri/0
Xiaptm1Hs/Xiaptm1Hs
B6.Cg-Xiaptm1Hs Tg(IghMyc)22Bri
|
decreased B cell proliferation |
J:138979
|
|
decreased leukocyte cell number |
J:138979
|
|
increased B cell apoptosis |
J:138979
|
|
normal
mortality/aging |
J:138979
|
Tg(IghMyc)186Brn/0
Rpl24Bst/Rpl24+
involves: C57BL/LiA * C57BLKS * CBA/BrA
|
normal
cellular phenotype |
J:142390
|
|
normal
immune system phenotype |
J:142390
|
|
increased apoptosis |
J:142390
|
|
normal
neoplasm |
J:142390
|
Tg(IghMyc)186Brn/0
Rpl38tm1Rugg/Rpl38+
involves: C57BL/LiA * CBA/BrA
|
normal
cellular phenotype |
J:142390
|
|
increased apoptosis |
J:142390
|
|
normal
neoplasm |
J:142390
|
Tg(MMTV-Cdc37)1Stp/0
Tg(MMTV-Myc)141-3Led/0
involves: C57BL/6 * CD-1 * DBA/2 * FVB/N
|
increased Leydig cell number |
J:62465
|
|
increased Leydig cell tumor incidence |
J:62465
|
|
increased lymphoma incidence |
J:62465
|
|
increased mammary adenocarcinoma incidence |
J:62465
|
|
increased mammary gland tumor incidence |
J:62465
|
|
increased salivary adenocarcinoma incidence |
J:62465
|
|
increased tumor incidence |
J:62465
|
Tg(MMTV-Myc)141-3Led/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Kras2)12Hev/0
involves: C57BL/6J * CD-1 * FVB/N
|
increased mammary gland tumor incidence |
J:133578
|
Tg(WapMyc)212Bri/0
Tg(WapTgfa)215Bri/0
involves: C57BL/6 * SJL
|
abnormal involution of the mammary gland |
J:56318
|
|
abnormal lactation |
J:56318
|
|
increased mammary gland tumor incidence |
J:56318
|
|
mammary gland hyperplasia |
J:56318
|
|
premature death |
J:56318
|
Trp53tm1.1Thst/Trp53+
Tg(IghMyc)22Bri/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL * SJL
|
increased lymphoma incidence |
J:198482
|
|
premature death |
J:198482
|
Trp53tm1Thst/Trp53+
Tg(IghMyc)22Bri/0
involves: 129S1/Sv * 129X1/SvJ * C57BL * SJL
|
increased lymphoma incidence |
J:198482
|
|
premature death |
J:198482
|
Trp53tm2.1Thst/Trp53+
Tg(IghMyc)22Bri/0
involves: 129 * C57BL * SJL
|
premature death |
J:282255
|
Ube2otm1.1(KOMP)Mbp/Ube2otm1.1(KOMP)Mbp
Tg(IghMyc)22Bri/0
involves: C57BL * C57BL/6N * FVB/N * SJL
|
decreased survivor rate |
J:239679
|
|
increased B cell derived lymphoma incidence |
J:239679
|
Excel File
Analysis Tools